000			02313cam a2200337 a 4500
003			EG-GiCUC
005			20250223031854.0
008			171209s2017 ua dh f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aDeposite
097			_aPh.D
099			_aCai01.08.08.Ph.D.2017.He.S
100	0		_aHeba Ibrahim Mohamed Abdallah
245	1	0	_aStudy the effect of nano and micro encapsulation of DNA vaccine model on its stability and immunogenicity / _cHeba Ibrahim Mohamed Abdallah ; Supervised Mahmoud Mohamed Ghorab , Aly Fahmy Mohamed
246	1	5	_aدراسة تأثير الصياغة على الثبات والقدرة المناعية لنموذج لقاح حامض الديكسيريبوز فى صورة حويصلات دقيقة او نانو مترية
260			_aCairo : _bHeba Ibrahim Mohamed Abdallah , _c2017
300			_a172 P. : _bcharts , facsimiles ; _c25cm
502			_aThesis (Ph.D.) - Cairo University - Faculty of Pharmacy - Department of Pharmaceutics
520			_aHerpes simplex virus type 2 (HSV-2) is a one of the most prevalent worldwide sexually transmitted infection. HSV-2 causes recurrent genital ulcers, neonatal herpes, and also, increases the risk for human immunodeficiency virus (HIV) acquisition. Many HSV-2 vaccines have been tested in humans, but were not consistently effective. In the present work we tried to produce a model vaccine for HSV-2 formulated in different formulae as an attempt for development of an effective prophylactic and therapeutic HSV-2 vaccine. Beta propiolactone (BPL) as a virus inactivant was compared with the conventional formalin (F). Gold and silver nanoparticles were prepared with different concentrations as a vaccine adjuvants. Also, calcium phosphate nanoparticles and bovine serum albumin nanoparticles were used as vaccine adjuvants . They were compared with currently used aluminum phosphate gel (alum) microparticles
530			_aIssued also as CD
653		4	_aDNA
653		4	_aDNA vaccine model
653		4	_aNano and micro encapsulation
700	0		_aAly Fahmy Mohamed, _eSupervisor
700	0		_aMahmoud Mohamed Ghorab , _eSupervisor
856			_uhttp://172.23.153.220/th.pdf
905			_aNazla _eRevisor
905			_aShimaa _eCataloger
942			_2ddc _cTH
999			_c63916 _d63916